Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for advanced cancer patients. The ADC trastuzumab emtansine, has shown excellent anti-tumor activity in patients with HER2-positive metastatic breast cancer. Other ADCs in development likewise show high anti-tumor activity and adverse effects are generally mild.7 Over two dozen ADCs are currently in clinical trials for solid tumors and blood cancer.6

 


Continue Reading